{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T05:13:17Z","timestamp":1768799597169,"version":"3.49.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,18]]},"DOI":"10.7759\/cureus.101787","type":"journal-article","created":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T16:11:17Z","timestamp":1768752677000},"source":"Crossref","is-referenced-by-count":0,"title":["Pembrolizumab in Practice: Assessing Safety and Effectiveness Through a Retrospective Frame"],"prefix":"10.7759","author":[{"given":"Shalini","family":"Thomas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Princy","family":"Palatty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laxmi","family":"Govindraj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Visalakshi","family":"Potukuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1586\/14737140.2016.1123626","article-title":"Pembrolizumab for the treatment of PD-L1 positive advanced or metastatic non-small cell lung cancer","volume":"16","author":"Dang TO","year":"2016","unstructured":"Dang TO, Ogunniyi A, Barbee MS, Drilon A. Pembrolizumab for the treatment of PD-L1 positive advanced or metastatic non-small cell lung cancer. Expert Rev Anticancer Ther. 2016, 16:13-20. 10.1586\/14737140.2016.1123626","journal-title":"Expert Rev Anticancer Ther"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpheart.00378.2023","article-title":"Immune interactions in pembrolizumab (PD-1 inhibitor) cancer therapy and cardiovascular complications","volume":"325","author":"Banerjee A","year":"2023","unstructured":"Banerjee A, Narasimhulu CA, Singla DK. Immune interactions in pembrolizumab (PD-1 inhibitor) cancer therapy and cardiovascular complications. Am J Physiol Heart Circ Physiol. 2023, 325:H751-67. 10.1152\/ajpheart.00378.2023","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-02023-w","article-title":"Regulatory mechanisms of PD-1\/PD-L1 in cancers","volume":"23","author":"Lin X","year":"2024","unstructured":"Lin X, Kang K, Chen P, et al.. Regulatory mechanisms of PD-1\/PD-L1 in cancers. Mol Cancer. 2024, 23:108. 10.1186\/s12943-024-02023-w","journal-title":"Mol Cancer"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S151023","article-title":"Clinical utility of pembrolizumab in the management of advanced solid tumors: an evidence-based review on the emerging new data","volume":"11","author":"du Rusquec P","year":"2019","unstructured":"du Rusquec P, de Calbiac O, Robert M, Campone M, Frenel JS. Clinical utility of pembrolizumab in the management of advanced solid tumors: an evidence-based review on the emerging new data. Cancer Manag Res. 2019, 11:4297-312. 10.2147\/CMAR.S151023","journal-title":"Cancer Manag Res"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-024-00690-x","article-title":"Cancer therapy with antibodies","volume":"24","author":"Paul S","year":"2024","unstructured":"Paul S, Konig MF, Pardoll DM, et al.. Cancer therapy with antibodies. Nat Rev Cancer. 2024, 24:399-426. 10.1038\/s41568-024-00690-x","journal-title":"Nat Rev Cancer"},{"key":"ref6","article-title":"Pembrolizumab","author":"Flynn JP","year":"2025","unstructured":"Flynn JP, Gerriets V. Pembrolizumab. StatPearls Publishing, Treasure Island (FL); 2025."},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.62347\/LQWY8309","article-title":"Efficacy and safety of pembrolizumab in the treatment of advanced non-small cell lung cancer: a systematic review and meta-analysis","volume":"17","author":"Gao K","year":"2025","unstructured":"Gao K, Yimin N, Song B, Pan H, Lu Z. Efficacy and safety of pembrolizumab in the treatment of advanced non-small cell lung cancer: a systematic review and meta-analysis. Am J Transl Res. 2025, 17:16-27. 10.62347\/LQWY8309","journal-title":"Am J Transl Res"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2020.107281","article-title":"Safety and efficacy of pembrolizumab plus lenvatinib versus pembrolizumab and lenvatinib monotherapies in cancers: a systematic review","volume":"91","author":"Mo DC","year":"2021","unstructured":"Mo DC, Luo PH, Huang SX, Wang HL, Huang JF. Safety and efficacy of pembrolizumab plus lenvatinib versus pembrolizumab and lenvatinib monotherapies in cancers: a systematic review. Int Immunopharmacol. 2021, 91:107281. 10.1016\/j.intimp.2020.107281","journal-title":"Int Immunopharmacol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2016-543","article-title":"Abstract 543: Preclinical combination strategies to enhance the efficacy of the anti-PD-1 antibody pembrolizumab","volume":"76","author":"Pinheiro EM","year":"2016","unstructured":"Pinheiro EM, Hinton M, Mangadu R, et al.. Abstract 543: Preclinical combination strategies to enhance the efficacy of the anti-PD-1 antibody pembrolizumab. Cancer Res. 2016, 76:543. 10.1158\/1538-7445.AM2016-543","journal-title":"Cancer Res"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer","volume":"372","author":"Garon EB","year":"2015","unstructured":"Garon EB, Rizvi NA, Hui R, et al.. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015, 372:2018-28. 10.1056\/NEJMoa1501824","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-025-03989-0","article-title":"Lenvatinib plus pembrolizumab compared to carboplatin plus paclitaxel for carboplatin and paclitaxel pretreated, recurrent, or advanced endometrial cancer","volume":"23","author":"Wang SJ","year":"2025","unstructured":"Wang SJ, Sun L, Shih YH, et al.. Lenvatinib plus pembrolizumab compared to carboplatin plus paclitaxel for carboplatin and paclitaxel pretreated, recurrent, or advanced endometrial cancer. BMC Med. 2025, 23:160. 10.1186\/s12916-025-03989-0","journal-title":"BMC Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.iotech.2022.100178","article-title":"The safety, tolerability, and preliminary antitumor activity of sitravatinib plus tislelizumab in metastatic triple-negative breast cancer: a phase II trial","volume":"16","author":"Liu L","year":"2022","unstructured":"Liu L, Fan L, Jin X, et al.. The safety, tolerability, and preliminary antitumor activity of sitravatinib plus tislelizumab in metastatic triple-negative breast cancer: a phase II trial. Immuno-Oncol Technol. 2022, 16:100178. 10.1016\/j.iotech.2022.100178","journal-title":"Immuno-Oncol Technol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-0663","article-title":"FDA approval summary: accelerated approval of pembrolizumab for second-line treatment of metastatic melanoma","volume":"23","author":"Chuk MK","year":"2017","unstructured":"Chuk MK, Chang JT, Theoret MR, et al.. FDA approval summary: accelerated approval of pembrolizumab for second-line treatment of metastatic melanoma. Clin Cancer Res. 2017, 23:5666-70. 10.1158\/1078-0432.CCR-16-0663","journal-title":"Clin Cancer Res"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2017-00448","article-title":"Pembrolizumab-induced thyroiditis: comprehensive clinical review and insights into underlying involved mechanisms","volume":"102","author":"Delivanis DA","year":"2017","unstructured":"Delivanis DA, Gustafson MP, Bornschlegl S, et al.. Pembrolizumab-induced thyroiditis: comprehensive clinical review and insights into underlying involved mechanisms. J Clin Endocrinol Metab. 2017, 102:2770-80. 10.1210\/jc.2017-00448","journal-title":"J Clin Endocrinol Metab"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1080\/1120009X.2025.2468045","article-title":"Pembrolizumab associated immune thrombocytopenia","author":"Perkin P","year":"2025","unstructured":"Perkin P, Sekmek S, Bayram D, Tugba Kos F. Pembrolizumab associated immune thrombocytopenia. J Chemother. 2025, 1-5. 10.1080\/1120009X.2025.2468045","journal-title":"J Chemother"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1159\/000543278","article-title":"Adjuvant therapy with pembrolizumab in renal cell carcinoma: real-world experiences from a retrospective, multi-institutional cohort","volume":"109","author":"Mattigk A","year":"2025","unstructured":"Mattigk A, Cano Garcia C, Kl\u00fcmper N, et al.. Adjuvant therapy with pembrolizumab in renal cell carcinoma: real-world experiences from a retrospective, multi-institutional cohort. Urol Int. 2025, 109:291-8. 10.1159\/000543278","journal-title":"Urol Int"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0000000000000271","article-title":"Association between pembrolizumab-related adverse events and treatment outcome in advanced melanoma: results from the Dutch expanded access program","volume":"42","author":"Bisschop C","year":"2019","unstructured":"Bisschop C, Wind TT, Blank CU, et al.. Association between pembrolizumab-related adverse events and treatment outcome in advanced melanoma: results from the Dutch expanded access program. J Immunother. 2019, 42:208-14. 10.1097\/CJI.0000000000000271","journal-title":"J Immunother"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01598","article-title":"Phase IB\/II trial of lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma, endometrial cancer, and other selected advanced solid tumors","volume":"38","author":"Taylor MH","year":"2020","unstructured":"Taylor MH, Lee CH, Makker V, et al.. Phase IB\/II trial of lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma, endometrial cancer, and other selected advanced solid tumors. J Clin Oncol. 2020, 38:1154-63. 10.1200\/JCO.19.01598","journal-title":"J Clin Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/451089-pembrolizumab-in-practice-assessing-safety-and-effectiveness-through-a-retrospective-frame","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T16:11:17Z","timestamp":1768752677000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/451089-pembrolizumab-in-practice-assessing-safety-and-effectiveness-through-a-retrospective-frame"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,18]]},"references-count":18,"URL":"https:\/\/doi.org\/10.7759\/cureus.101787","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1,18]]}}}